Welcome to our dedicated page for VolitionRX news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on VolitionRX stock.
VolitionRx Limited (VNRX) is a U.S.-based epigenetics company at the forefront of developing non-invasive blood tests for early detection and monitoring of life-altering diseases, including various cancers. By leveraging their proprietary Nucleosomics™ platform, VolitionRx is pioneering diagnostic tests that identify and measure nucleosomes in the bloodstream, indicating the presence of disease.
The company's goal is to make these blood tests as commonplace and straightforward as current diabetic and cholesterol tests. VolitionRx operates through subsidiaries, with its primary research and development activities based in Belgium. The company also has offices in the U.S., London, and Singapore, focusing on bringing revolutionary diagnostic products to market across Europe, the U.S., and globally.
VolitionRx's innovative product portfolio includes the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. The company has recently expanded into veterinary diagnostics with the Nu.Q® Vet Cancer Test, now available in Japan through a partnership with Fujifilm Vet Systems and in the U.S. and Europe through Antech Diagnostics. This expansion aims to provide veterinarians with simple, cost-effective tools for early cancer detection in dogs.
In 2023, VolitionRx achieved several milestones, including significant partnerships and the commercialization of its veterinary products. The company also made strides in its human diagnostics pipeline, with plans to advance its regulatory pathway with the U.S. FDA and large-scale clinical studies scheduled for publication.
VolitionRx remains focused on advancing the science of epigenetics to improve patient outcomes. The company aims to achieve cash flow neutrality by 2025 through a mix of revenue growth, milestone payments from licensing agreements, and cost reduction measures.
For more information, visit www.volitionrx.com, or follow them on Twitter, LinkedIn, and Facebook.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled a conference call on May 14, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024 and provide a business update. The call will be hosted by key executives and will include details on important events and upcoming milestones.